Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
about
Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical modelPD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Role of Natural Killer Cells in HIV-Associated Malignancies.Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.Cellular immunity augmentation in mainstream oncologic therapyProtective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins.Immune checkpoint inhibitors in cancer therapy.CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?Informatics for cancer immunotherapy.Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.In-vitro effect of pembrolizumab on different T regulatory cell subsets.Inhibitors of the PD-1 Pathway in Tumor Therapy.Checks and Balances in Autoimmune Vasculitis.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.CD8 + T-cell responses in vaccination: reconsidering targets and function in the context of chronic antigen stimulation.Diagnostic value of peripheral blood immune profiling in colorectal cancer.The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.Current status and future directions of cancer immunotherapy.DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
P2860
Q33728672-25842C67-B9FC-400E-9195-9C5895A19173Q33839204-C5E4C64F-B271-41BC-8F3E-A2B639D6829FQ37712593-6A19F421-BCA1-464C-9C1D-1598E13A46CCQ37730163-4F03B36E-D732-4587-8459-EEE9F3824CC0Q38557424-1B07242E-8EC1-433C-A2CE-BDAF75D19F40Q42938763-CD8DD575-AFF0-4C14-8111-85953F23692BQ45871487-E92FB3CC-50A4-498A-A07B-2BB58BCEE3ADQ45874696-B01DC5DB-69DD-4E95-A9AA-694ADAFB70AEQ47134263-3C7B3654-0F22-48CF-8CCA-772AD047A449Q47285613-4E1B725B-8454-4F27-AFAD-54A6FBC584C8Q47290509-D7A97DF1-CE5A-4029-BAF9-AD1A53F6CA79Q47399053-BFF747DB-1F33-45C3-9026-602601635081Q47616276-D02D5325-649E-4C00-B864-A00FE116338AQ48293633-1E6C0E6A-8AD5-4D36-ADDC-D1BB13461C05Q51764698-20CDEB17-D302-46C1-B035-6466B62AC461Q53047113-87603868-A25F-4CFC-B716-7081233DC4AAQ54209283-D9274540-3647-4EA5-8A34-253B1248B7FEQ54942183-05253F35-9E85-4D1C-924E-4931859D72F3Q54983490-B951FD9C-B458-4D3E-94F7-1012A6D88177Q55070491-3738D2BB-D142-4B69-910B-8812467736B9Q55425717-FA3AD4C9-3438-4D29-805D-AA7636B22731Q57816676-7EC1AB5B-9914-48CE-B2F3-5BA88421799A
P2860
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@ast
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@en
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@nl
type
label
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@ast
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@en
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@nl
prefLabel
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@ast
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@en
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@nl
P2093
P2860
P3181
P356
P1476
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
@en
P2093
P2860
P3181
P356
10.3389/FONC.2016.00233
P407
P577
2016-11-01T00:00:00Z